Mural Oncology Grants Stock Options and Restricted Stock Units to New Employees as Part of 2024 Inducement Plan
Mural Oncology Grants Stock Options and Restricted Stock Units to New Employees as Part of 2024 Inducement Plan
The stock options vest over four years, with 25% vesting on the first anniversary and 6.25% quarterly thereafter.Mural Oncology granted stock options and restricted stock units to four new employees as part of their inducement plan.
Mural Oncology向四名新員工授予了期權和限制性股票單位，作爲其誘導計劃的一部分。
Quiver AI Summary
Quiver AI 概要
Mural Oncology plc, a clinical-stage immuno-oncology company, announced on December 2, 2024, the granting of stock options and restricted stock units to four new employees as part of its 2024 Inducement Stock Option and Incentive Plan. The grants include a total of 26,300 stock options at an exercise price of $4.18 per share and 13,200 restricted stock units, intended to incentivize the new hires. The stock options have a ten-year term and vest over four years, along with similar vesting terms for the restricted stock units, both contingent on continued employment. Mural Oncology focuses on developing innovative cytokine therapies for cancer treatment, with its lead candidate, nemvaleukin, in trials for mucosal melanoma and platinum-resistant ovarian cancer.
Mural Oncology plc是一家臨床階段的免疫腫瘤學公司，於2024年12月2日宣佈向四名新員工授予期權和限制性股票單位，作爲其2024年誘導期權和激勵計劃的一部分。授予包括總計26,300個期權，行使價格爲每股4.18美元，以及13,200個限制性股票單位，旨在激勵新員工。這些期權的有效期爲十年，並在四年內歸屬，限制性股票單位也遵循類似的歸屬條款，均需在職。Mural Oncology專注於開發創新的細胞因子療法用於癌症治療，其主要候選藥物nemvaleukin正在進行粘膜黑色素瘤和鉑耐藥性卵巢癌的試驗。
Potential Positives
潛在的積極因素
- The company is demonstrating growth and attracting talent by granting stock options and restricted stock units to newly hired employees, which can enhance employee retention and motivation.
- The inducement awards are a strategic move in compliance with Nasdaq regulations, showcasing the company's commitment to operate within established guidelines.
- By providing equity-based compensation, Mural Oncology aligns employee interests with the company's long-term performance, potentially fostering a culture of ownership and investment in the company's success.
- Mural Oncology's ongoing clinical trials for its lead candidate, nemvaleukin, indicates active development in the competitive oncology space, which could lead to significant breakthroughs in cancer treatment.
- 該公司通過向新僱傭的員工授予期權和限制性股票單位，展示了增長和吸引人才的能力，這可以增強員工的留任和積極性。
- 誘導獎勵是遵循納斯達克法規的戰略舉措，展示了公司在既定指導方針內運營的承諾。
- 通過提供基於股權的薪酬，Mural Oncology將員工利益與公司長期績效對齊，可能促進擁有和投資於公司成功的文化。
- Mural Oncology正在對其主要候選藥物nemvaleukin進行持續的臨床試驗，表明在競爭激烈的腫瘤學領域的積極發展，這可能導致癌症治療的重大突破。
Potential Negatives
潛在負面影響
- Granting non-statutory stock options and restricted stock units may indicate a reliance on equity compensation to attract talent, suggesting potential difficulties in attracting or retaining employees through traditional compensation methods.
- The press release details stock options and restricted stock units for new hires, which may raise concerns about dilution of existing shareholders' equity if such stocks are exercised or vested in large quantities.
- The need to incentivize newly hired employees through stock options and restricted stock units may signal that the company is still in the early stages of its growth and may not yet be able to offer competitive salaries or benefits compared to more established firms in the industry.
- 授予非法定期權和限制性股票單位可能表明公司依賴股權補償來吸引人才，這暗示着通過傳統補償方式吸引或留住員工可能面臨潛在困難。
- 新聞稿詳細說明了新員工的期權和限制性股票單位，這可能引發對現有股東股權稀釋的擔憂，如果這些股票以大額行使或歸屬。
- 通過期權和限制性股票單位激勵新僱員的必要性可能表明公司仍處於成長的早期階段，可能尚無法提供與行業中更成熟公司競爭的薪資或福利。
FAQ
常見問題
What stock options were granted by Mural Oncology?
Mural Oncology授予了哪些期權？
Mural Oncology granted non-statutory stock options to purchase 26,300 ordinary shares to four newly hired employees.
Mural Oncology向四名新招聘員工授予購買26,300股普通股的非法定期權。
What are the vesting terms for the stock options?
期權的歸屬條款是什麼？
The stock options vest over four years, with 25% vesting on the first anniversary and 6.25% quarterly thereafter.
該期權在四年內歸屬，第一週年歸屬25%，此後每季度歸屬6.25%。
How many restricted stock units were granted?
授予了多少限制性股票單位？
The company granted restricted stock units for an aggregate of 13,200 ordinary shares as part of the inducement package.
公司授予了總計13,200股普通股的限制性股票單位，作爲誘因方案的一部分。
What is Mural Oncology's main focus?
Mural Oncology的主要關注點是什麼？
Mural Oncology focuses on developing novel engineered cytokine therapies for patients with various types of cancers.
Mural Oncology專注於爲多種類型癌症患者開發新型工程細胞因子療法。
Where is Mural Oncology headquartered?
Mural Oncology的總部在哪裏？
Mural Oncology has its registered office in Dublin, Ireland, with primary facilities in Waltham, Massachusetts.
Mural Oncology的註冊辦公室位於愛爾蘭都柏林，主要設施位於馬薩諸塞州的沃爾瑟姆。
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
免責聲明：這是由GlobeNewswire分發的新聞稿的人工智能生成摘要。用於總結這份稿件的模型可能會出錯。請在這裏查看完整發布。
$MURA Insider Trading Activity
$MURA內部交易活動
$MURA insiders have traded $MURA stock on the open market 5 times in the past 6 months. Of those trades, 1 have been purchases and 4 have been sales.
$MURA內部人員在過去6個月中在公開市場上進行了5次$MURA股票交易。在這些交易中，有1次是購買，4次是出售。
Here's a breakdown of recent trading of $MURA stock by insiders over the last 6 months:
以下是$MURA股票近6個月內部人員的最新交易情況：
- VICKI L GOODMAN (Chief Medical Officer) sold 5,069 shares.
- ADAM D. CUTLER (Chief Financial Officer) sold 7,421 shares.
- SUSAN ALTSCHULLER purchased 10,000 shares.
- MAIKEN KESON-BROOKES (See Remarks) sold 2,157 shares.
- CAROLINE LOEW (Chief Executive Officer) sold 12,531 shares.
- VICKI L GOODMAN（首席醫療官）出售了5,069股。
- ADAm D. CUTLER（首席財務官）出售了7,421股。
- SUSAN ALTSCHULLER購買了10,000股。
- MAIKEN KESON-BROOKES（見備註）出售了2,157股。
- CAROLINE LOEW（首席執行官）出售了12,531股。
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
要跟蹤內部交易，請查看Quiver Quantitative的內部交易特斯拉-儀表。
$MURA Hedge Fund Activity
$MURA對沖基金交易活動
We have seen 20 institutional investors add shares of $MURA stock to their portfolio, and 76 decrease their positions in their most recent quarter.
我們看到有20家機構投資者在最近的季度中增加了$MURA股票的持股，有76家機構減少了他們的持倉。
Here are some of the largest recent moves:
以下是一些最近最大的交易動態：
- WESTFIELD CAPITAL MANAGEMENT CO LP removed 743,495 shares (-100.0%) from their portfolio in Q3 2024
- BAKER BROS. ADVISORS LP removed 222,503 shares (-100.0%) from their portfolio in Q2 2024
- VERITION FUND MANAGEMENT LLC removed 170,847 shares (-33.4%) from their portfolio in Q3 2024
- NORGES BANK removed 168,511 shares (-100.0%) from their portfolio in Q2 2024
- NUVEEN ASSET MANAGEMENT, LLC removed 161,917 shares (-100.0%) from their portfolio in Q2 2024
- GOLDMAN SACHS GROUP INC removed 129,421 shares (-72.1%) from their portfolio in Q3 2024
- POINT72 ASSET MANAGEMENT, L.P. added 108,715 shares (+inf%) to their portfolio in Q3 2024
- WESTFIELD CAPITAL MANAGEMENT CO LP在2024年第三季度從其投資組合中移除了743,495股股票（-100.0%）。
- BAKER BROS. ADVISORS LP在2024年第二季度從其投資組合中移除了222,503股股票（-100.0%）。
- VERITION基金管理機構於2024年第三季度將其投資組合中的170,847股股票減少了（-33.4%）
- 挪威銀行於2024年第二季度將其投資組合中的168,511股股票移除了（-100.0%）
- NUVEEN資產管理公司於2024年第二季度將其投資組合中的161,917股股票移除了（-100.0%）
- 高盛集團股份有限公司於2024年第三季度將其投資組合中的129,421股股票減少了（-72.1%）
- POINT72資產管理公司於2024年第三季度向其投資組合中添加了108,715股股票（+inf%）
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
要追蹤對沖基金的股票組合，請查看Quiver Quantitative的機構持股儀表板。
Full Release
全面發佈
WALTHAM, Mass and DUBLIN, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers, today announced that on December 2, the Company granted to four newly hired employees (i) non-statutory stock options to purchase an aggregate of 26,300 ordinary shares of the Company and (ii) restricted stock units with respect to an aggregate of 13,200 ordinary shares of the Company, pursuant to the Company's 2024 Inducement Stock Option and Incentive Plan, each as an inducement material to the new employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
馬薩諸塞州沃爾瑟姆和都柏林，2024年12月03日（全球新聞社） - Mural Oncology plc（納斯達克股票代碼：MURA）是一家處於臨床階段的免疫腫瘤學公司，開發新穎的，調查中的工程細胞因子治療，旨在解決多種癌症患者所面臨的未滿足需求領域。公司今天宣佈，於12月2日向四名新僱員授予（i）購買公司共計26,300股普通股的非統計股票期權和（ii）限制性股票單位，涉及公司共計13,200股普通股，根據公司的2024年誘因股票期權和激勵計劃，每項均作爲對新員工按照納斯達克上市規則5635(c)(4)進入公司僱傭的誘因材料。
The stock options have an exercise price of $4.18 per share, which is equal to the closing price per share of the Company's ordinary shares as reported by Nasdaq on December 2, 2024. The options have a ten-year term and vest over four years, with 25% of the original number of shares vesting on the first anniversary of the grant date and 6.25% of the shares underlying the options vesting quarterly thereafter, subject to such employee's continued service with the Company through the applicable vesting dates. Each of the stock options is subject to the terms and conditions of a stock option award agreement covering the grant and the Company's 2024 Inducement Stock Option and Incentive Plan. The restricted stock units vest over four years, 25% per year on the anniversary of the grant date, subject to such employee's continued service with the Company through the applicable vesting dates. Each of the restricted stock units is subject to the terms and conditions of a restricted stock award agreement covering the grant and the Company's 2024 Inducement Stock Option and Incentive Plan.
這些股票期權的行使價格爲每股4.18美元，這與公司普通股在2024年12月2日納斯達克報告的收盤價格相等。期權的有效期爲十年，並在四年內分期兌現，其中25%的原始股份在授予日期的第一週年兌現，其後每季度兌現6.25%的期權股份，前提是該員工在相關兌現日期持續爲公司服務。每個股票期權都受限於股票期權授予協議的條款和條件，以及公司的2024年誘導股票期權和激勵計劃。限制性股票單位在四年內分期兌現，每年在授予日期的週年上兌現25%，前提是該員工在相關兌現日期持續爲公司服務。每個限制性股票單位均受限於適用於授予的限制性股票獎勵協議的條款和條件，以及公司的2024年誘導股票期權和激勵計劃。
About Mural Oncology
Mural Oncology is leveraging its novel protein engineering platform to develop cytokine-based immunotherapies for the treatment of cancer. By combining our expertise in cytokine biology and immune cell modulation and our protein engineering platform, we are developing medicines to deliver meaningful and clinical benefits to people living with cancer. Our mission is to broaden the potential and reach of cytokine-based immunotherapies to improve the lives of patients. Our lead candidate, nemvaleukin, is currently in potentially registrational trials in mucosal melanoma and platinum-resistant ovarian cancer. Mural Oncology has its registered office in Dublin, Ireland, and its primary facilities in Waltham, Mass. For more information, visit Mural Oncology's website at
and follow us on
LinkedIn
and
X
.
關於Mural Oncology
Mural Oncology正在利用其新型蛋白質工程平台開發基於細胞因子的免疫療法，以治療癌症。通過結合我們在細胞因子生物學和免疫細胞調節方面的專業知識以及我們的蛋白質工程平台，我們正在開發能爲癌症患者帶來實質性臨床益處的藥物。我們的使命是擴大基於細胞因子的免疫療法的潛力和覆蓋範圍，以改善患者的生活。我們首要候選藥物nemvaleukin目前正在粘膜黑色素瘤和鉑耐藥卵巢癌的潛在登記試驗中。Mural Oncology註冊辦事處位於愛爾蘭都柏林，主要設施位於馬薩諸塞州沃爾瑟姆。有關更多信息，請訪問Mural Oncology的網站。
並關注我們
LinkedIn
和
X
.
Contact
聯繫方式
Katie Sullivan
katie.sullivan@muraloncology.com
凱蒂·沙利文
katie.sullivan@muraloncology.com
